1.29
7.86%
-0.11
Handel nachbörslich:
1.28
-0.01
-0.78%
Schlusskurs vom Vortag:
$1.40
Offen:
$1.4
24-Stunden-Volumen:
84,810
Relative Volume:
5.40
Marktkapitalisierung:
$16.01M
Einnahmen:
$996.00K
Nettoeinkommen (Verlust:
$-6.09M
KGV:
0.2873
EPS:
4.49
Netto-Cashflow:
$-9.76M
1W Leistung:
-15.13%
1M Leistung:
-19.38%
6M Leistung:
-41.89%
1J Leistung:
-43.17%
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Vergleichen Sie TXMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
TXMD | 1.29 | 16.01M | 996.00K | -6.09M | -9.76M | 4.49 |
ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-12-02 | Eingeleitet | Guggenheim | Buy |
2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
2018-06-15 | Eingeleitet | JP Morgan | Overweight |
2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
2016-11-22 | Fortgesetzt | Jefferies | Buy |
2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
2016-11-07 | Fortgesetzt | Guggenheim | Buy |
2016-04-04 | Eingeleitet | Goldman | Buy |
2015-12-08 | Bestätigt | Jefferies | Buy |
2015-12-08 | Bestätigt | Stifel | Buy |
2015-09-21 | Bestätigt | Jefferies | Buy |
2015-06-09 | Eingeleitet | Guggenheim | Buy |
2014-07-08 | Eingeleitet | FBR Capital | Outperform |
2014-04-17 | Bestätigt | Noble Financial | Buy |
2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TXMD stock touches 52-week low at $1.43 amid market challenges - Investing.com
TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023) - Yahoo Finance
TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Large Increase in Short Interest - Defense World
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift - TipRanks
TherapeuticsMD: Q3 Earnings Snapshot - Houston Chronicle
TherapeuticsMD Inc (TXMD) Reports Third Quarter 2024 Earnings: S - GuruFocus.com
TherapeuticsMD Shifts Focus with Lower Q3 Losses - TipRanks
TherapeuticsMD Narrows Q3 Loss by 60%, Weighs Strategic Options Amid Revenue Growth | TXMD Stock News - StockTitan
TherapeuticsMD Inc. stock remains steady Monday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock remains steady Friday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock remains steady Wednesday, underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, still outperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock rises Thursday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock remains steady Thursday, underperforms market - MarketWatch
Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest Technology - Benzinga
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):